Home-new

Safe

Simple

Affordable

TCUBEit Provides Innovative T Cell-Based Immuno-Therapy

Cell Therapy

Pioneering Next-Generation Immunotherapy for Cancer and Rare Diseases

scroll down

We advance T cell therapies for cancer and neuroinflammatory diseases, spanning from discovery to clinical development.

We combine next-generation T cell manufacturing with innovative TCR-T therapies powered by stable monomeric TCRs.

We open new paths in cancer and rare disease care through next-generation T cell culture technology.

Investment Highlight

T-CAMP: MC-EXP+ T-CAST
(Optimize T-cell culture utilizing AI)

T-CAMP7, T-CAMP5: cell culture period of 5 – 7 days

Expand therapeutic T cells with improved
bio-persistence

Novel single variable domain TCR structure

Engineered transmembrane domain
to escape mispairing with endogeneous TCRs

mRNA platforms to increase convenience/safety

Independent underlying technology reduces safety/development ease/cost

Securing unexplored areas
using mRNA platform

Production/Proof using own GMP Compatible Cleanroom

Pre-A investment completed
: CK, IMM, KIP, Bokwang, Hanlim

Unicorn-company certified by
Korean government

Expansion through joint basic research
l 3 cases in progress

Expansion through joint basic research
3 cases in progress

Synergy through co-administration of immuno-cancer drugs | ICI

Expandability and flexibility of production processes l International Collaboration

Together

let’s build a safer and simpler

future for cell therapy